

24 April 2025

Treatment of Dermatological Conditions

Question 1. How many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products:

- Abrocitinib 7
- Acitretin **
- Alitretinoin **
- Azathioprine **
- Baricitinib <5
- Ciclosporin **
- Dupilumab 223
- Lebrikizumab 7
- Methotrexate **
- Mycophenolate mofetil **
- Pimecrolimus **
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only **
- Tacrolimus ointment
- Tralokinumab <5
- Upadacitinib 36
- Nemolizumab <5

24 April 2025

Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- **6 months to 5** <5
- **Age 6-11** 10
- **Age 12-17** 35
- **Age 18 and above** 227

** this information isn't currently retrievable via Encompass and it would take longer than 18 hours to attempt to extract. To undertake this exercise would necessitate a manual interrogation of data which would involve a significant number of hours.

This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Please note:

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.